Skip to content

Delivering World-Leading Multi-Cancer Early Detection

Harnessing microRNA discovery and multi-omics diagnostics to detect cancer early, when it is curable.

shutterstock_296282819shutterstock_296282819
Clarity in One Blood Draw
Detect Cancer Early, for Timely Life-saving Care
As the first clinical application of our industry-leading platform technology, we have launched GASTROClear, the world's first microRNA blood test for early detection of gastric cancer.

GASTROClear is a multi-microRNA biomarker test that complements gastric endoscopy in detecting stomach cancer early, when it can be cured.

Using our versatile platform, we are developing microRNA-centric, multi-biomarker tests for other high-incidence cancers, including lung, breast, colorectal, and liver cancer.
cdc-k0KRNtqcjfw-unsplashcdc-k0KRNtqcjfw-unsplash
COVID-19 Response
Testing Solutions Powered by Our Capabilities
We have responded to the call to fight the COVID-19 pandemic by drawing on our capabilities and experience in providing Accurate, Actionable, and Affordable diagnostic tests for cancer and cardiovascular diseases.

We offer complete COVID-19 testing solutions, starting from sample collection and preservation, through easy and reliable RNA extraction, to tested and proven SARS-CoV-2 RT-PCR diagnostic tests.

Applying technology and capabilities to power early cancer detection

GASTROClear, our first commercial diagnostic application, is the culmination of more than 10 years of discovery and more than 5 years of rigorous clinical validation. MiRXES continues to accelerate development and deployment of microRNA-centric, multi-biomarker testing solutions to meet the world's greatest healthcare challenges.

Play Video